Alnylam (ALNY) CEO Yvonne Greenstreet Receives 107-Share Award

What Happened

• Yvonne Greenstreet, CEO of Alnylam Pharmaceuticals (ALNY), was issued 107 shares of ALNY common stock on September 19, 2026. The Form 4 reports an acquisition (award) of 107 shares at a reported price of $0.00 (total reported value $0).
• This issuance is described as a service award tied to 10 years of continuous employment and includes shares issued net of minimum statutory tax withholding.

Key Details

• Transaction date: 2026-09-19; Form 4 filed: 2026-09-22 (filing appears timely; no late-filing flag reported).
• Transaction type/code: A (award/grant/acquisition).
• Price: $0.00 per share as reported on Form 4; total reported consideration $0.
• Shares owned after transaction: Not specified in the information provided on this summary.
• Footnotes:
  • F1: Committee approved a $50,000 value award for employees completing 10 years; the shares here were issued in recognition of Greenstreet’s 10 years of service and are shown net of statutory tax withholding.
  • F2: The filing also notes shares acquired under the ALNY 401(k) matching program (reflects matching-contribution shares).

Context

• This was an award/recognition for tenure, not an open-market purchase or sale; such awards are routine compensation and do not by themselves indicate insider buying or selling intent.
• The reporting shows shares issued net of tax withholding (common for equity awards). For retail investors, awards and employer matching indicate compensation practices but are not a direct signal of management’s view of the stock.